Alpha Tau Medical announced interim results from its U.S. trial of Alpha DaRT therapy for recurrent glioblastoma, showing all eight treated patients are alive with a median follow-up of 6.9 months and no median survival reached. Among six patients assessed, 100% achieved tumor response, including 83.3% complete responses, with no unexpected serious adverse events reported. The trial demonstrated 100% feasibility in treatment delivery and no local tumor recurrence, indicating promising potential for this difficult-to-treat brain cancer. The company plans to continue enrollment toward 20 patients and will provide further updates as follow-up scans clarify long-term outcomes.
Alpha Tau's interim trial results for Alpha DaRT therapy provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 16, 2026 00:01 WIB: out of 150 priced US health stocks, 71 rose and 77 fell. Ionis Pharmaceuticals (IONS) gained 6.41% to USD 29.06 with a typical hold time of 5 days, contrasting with Butterfly Network (BFLY) and Alumis (ALMS), which fell by 8.85% and 8.65% to USD 6.08 and USD 5.60, respectively, with longer hold times of 19 and 18 days.
Over the past week, the cryptocurrency Aero (AERO) experienced a significant drop of 27%, which is a larger decline compared to the losses seen in major cryptocurrencies Bitcoin (BTC) and Ether (ETH). This sharp decrease highlights increased volatili...
CVS Health's analysis of Aetna insurance data shows that GLP-1 drugs, used for obesity and diabetes, could help employers and health plans break even if priced under $350 per month. These drugs reduce emergency room visits by 10%-12% and hospitalizat...
P2Pool V2 is a new protocol operating on Bitcoin's testnet that decentralizes the verification of mining work and earnings accounting by shifting these tasks from centralized pool operators to individual nodes. This reduces the control pool operators...
Viking Therapeutics reported that 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, with no patients experiencing BMI worsening. The Phase 2 VENTURE trial also showed significant improvemen...
In Q3 2026, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index, driven by strong holdings in Information Technology, Financials, and Consumer Staples sectors. The fund's success was attributed to company-specific fundam...
